Consolidated Capital Management’s Boston Scientific BSX Stock Holding History

Consolidated Capital Management’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,735	Closed	-$261K	–	76
2025 Q4	$261K	Hold	2,735	–	–	0.08%	63
2025 Q3	$267K	Hold	2,735	–	–	0.09%	43
2025 Q2	$294K	Hold	2,735	–	–	0.11%	41
2025 Q1	$276K	Hold	2,735	–	–	0.11%	41
2024 Q4	$244K	Hold	2,735	–	–	0.11%	35
2024 Q3	$229K	Hold	2,735	–	–	0.1%	34
2024 Q2	$211K	Buy	+2,735	New	+$200K	0.1%	38
2021 Q2	–	Sell	-6,471	Closed	-$250K	–	43
2021 Q1	$250K	Buy	+6,471	New	+$245K	0.12%	38

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Consolidated Capital Management's BSX Position: Q1 2026 in Review

Consolidated Capital Management sold out of Boston Scientific (BSX) in Q1 2026, closing a stake of 2,735 shares — an estimated $261K sold.

Consolidated Capital Management first reported a position in BSX in Q1 2021 and held it in 8 quarters. The position peaked at $294K in Q2 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Consolidated Capital Management reported no remaining Boston Scientific position as of Q1 2026 after selling out during the quarter.
Consolidated Capital Management sold 2,735 Boston Scientific shares in Q1 2026, an estimated $261K.
Consolidated Capital Management first reported a position in Boston Scientific in Q1 2021 and held it in 8 quarters.
Consolidated Capital Management's Boston Scientific position peaked at $294K in Q2 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Consolidated Capital Management's 13F filing for Q1 2026, filed 15 Apr 2026.